Harmony Biosciences CMO sells 38K shares
Harmony Biosciences’ chief medical officer exercised options for 38,452 HRMY shares and sold an equal number under a Rule 10b5-1 trading plan at weighted average prices near $43.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Harmony Biosciences Holdings, Inc. (HRMY) reported that its Chief Medical Officer, Kumar Budur, exercised stock options and sold shares over September 16–18, 2026. He exercised options covering 38,452 shares of Common Stock at exercise prices of $30.69 and $30.27, then sold 38,452 shares in open-market transactions at weighted average prices around $43 per share pursuant to a Rule 10b5-1 trading plan.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option F4 | 10,406 | $0.00 | $0.00 |
| Exercise | Stock Option F5 | 25,446 | $0.00 | $0.00 |
| Exercise | Common Stock | 10,406 | $30.69 | $319K |
| Exercise | Common Stock | 25,446 | $30.27 | $770K |
| Sale | Common Stock F1, F3 | 35,852 | $43.0545 | $1.54M |
| Exercise | Stock Option F4 | 400 | $0.00 | $0.00 |
| Exercise | Stock Option F5 | 400 | $0.00 | $0.00 |
| Exercise | Common Stock | 400 | $30.69 | $12K |
| Exercise | Common Stock | 400 | $30.27 | $12K |
| Sale | Common Stock F1 | 800 | $43.00 | $34K |
| Exercise | Stock Option F4 | 900 | $0.00 | $0.00 |
| Exercise | Stock Option F5 | 900 | $0.00 | $0.00 |
| Exercise | Common Stock | 900 | $30.69 | $28K |
| Exercise | Common Stock | 900 | $30.27 | $27K |
| Sale | Common Stock F1, F2 | 1,800 | $43.0146 | $77K |
Footnotes (5)
- F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.03. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.20. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4. The stock option vests with respect to 25% of the underlying shares on January 24, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
- F5. The stock option vests with respect to 25% of the underlying shares on May 1, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
weighted average price financial
stock option financial
derivative security financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did HRMY’s Chief Medical Officer report on this Form 4?
At what prices were the HRMY stock options exercised by the CMO?
Were the HRMY insider sales made under a Rule 10b5-1 trading plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.